QIAGEN N.V. — FY2016 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2016. This is an annual report, not a standalone fourth-quarter filing. Financial statements are prepared under U.S. GAAP and audited; the auditor issued unqualified opinions on the financial statements and internal control over financial reporting.
Business context
QIAGEN provides molecular testing and “Sample to Insight” products, including consumables, instruments, and bioinformatics, to Molecular Diagnostics, Applied Testing, Pharma, and Academia customers. Consumables and related revenues represented 87% of 2016 sales; instruments represented 13%. The company acquired Exiqon in 2016 and operated as one reportable segment.
Key financial metrics
| Metric | FY2016 | FY2015 |
|---|---|---|
| Net sales | $1,338.0 million | $1,281.0 million |
| Gross profit / gross margin | $844.7 million / 63% | $826.7 million / 65% |
| Operating income / operating margin | $98.8 million / 7.4% | $179.5 million / 14.0% |
| Net income attributable to QIAGEN / diluted EPS | $80.4 million / $0.34 | $130.1 million / $0.55 |
| Cash from operating activities | $341.6 million | $317.5 million |
| Cash and cash equivalents | $439.2 million | $290.0 million |
| Working capital | $729.1 million | $693.0 million |
| Total assets / total equity | $4,308.2 million / $2,607.1 million | $4,179.1 million / $2,568.1 million |
At year-end, short-term investments were $93.0 million and reported long-term debt was $1,067.1 million, with no current portion. The €400 million revolving credit facility was undrawn; total available undrawn credit facilities were approximately $460 million. The company reported $74.5 million of capital expenditures and $90.5 million of acquisition cash payments in 2016.
Changes versus comparable periods
- Sales rose 4% reported year over year, despite an approximately two-percentage-point currency headwind. Management attributed roughly four percentage points of growth to organic expansion and nearly two points to acquisitions. Excluding currency effects and the expected U.S. HPV sales decline, sales grew approximately 8%.
- Sales increased across product categories: consumables and related revenues rose 5%, and instruments rose 3%. By customer class, reported growth was 4% in Molecular Diagnostics, 5% in Applied Testing, 5% in Pharma, and 4% in Academia.
- U.S. HPV test sales declined 29% to $33 million, a continuing headwind. Molecular Diagnostics excluding U.S. HPV grew 7%.
- Gross margin declined two percentage points. Operating income fell 45% and QIAGEN-attributable net income fell 38%, reflecting increased operating expenses and restructuring-related costs.
- Operating cash flow increased to $341.6 million from $317.5 million. Cash and cash equivalents rose by $149.2 million during 2016.
Outlook, management commentary, risks, and unusual items
- Restructuring: Actions initiated in Q4 2016 included site and organizational changes, shared-service expansion, and sales and marketing realignment. QIAGEN recorded a $79.1 million pretax charge, including approximately $42.4 million of non-cash items, and expected approximately $10 million of additional pretax charges in 2017. The program’s estimated total cost was approximately $90 million.
- Shareholder returns: QIAGEN completed a synthetic share repurchase in January 2017, returning approximately $244 million through a capital repayment and reverse stock split. It planned additional open-market repurchases in 2017 toward a stated $300 million total capital-return commitment.
- Products and growth initiatives: Management highlighted QuantiFERON-TB, QIAsymphony, GeneReader NGS, personalized healthcare, and bioinformatics. GeneReader reached 55–60 placements by year-end 2016. QuantiFERON-TB sales exceeded $140 million in 2016; QuantiFERON-TB Gold Plus had been submitted to the FDA for premarket approval.
- Legal matter: A U.S. court issued a preliminary injunction in September 2016 in a competitor’s patent case involving GeneReader. QIAGEN relaunched the U.S. workflow with new sequencing chemistry, began early access in December, and targeted full commercialization for early 2017. A trial was scheduled for November 2017. Management did not expect a material impact on its 2017 financial outlook, but litigation outcomes remain uncertain.
- Taxes and earnings: QIAGEN reported a $23.4 million income tax benefit and a negative 41.1% effective tax rate, versus a 4.7% rate in 2015. The filing attributes the unusual rate partly to foreign tax effects and the lower pretax income base. This tax benefit supported reported net income despite lower pretax income.
- Other risks: Key exposures include product adoption and regulatory approvals, reimbursement and pricing pressure, competition, acquisitions and integration, foreign exchange, government and research funding, supplier or logistics interruptions, cybersecurity and privacy, and substantial debt. Goodwill and intangible assets were approximately $1.93 billion and $557 million, respectively.
- Accounting revision: QIAGEN retrospectively changed its share-based compensation attribution method from straight-line to accelerated recognition, revising prior-period figures. The filing also reports a $21.4 million intangible-asset impairment related to the 2016 restructuring and an $8.3 million impairment of an equity-method investment.
No clear quantitative full-year 2017 sales or earnings guidance is provided in the filing text.
Most important facts for investors to verify
- Reconcile the $79.1 million restructuring charge, its cash and non-cash components, and expected remaining 2017 costs; assess whether anticipated savings materialize.
- Track organic growth and currency effects separately, particularly the continuing decline in U.S. HPV sales and growth in Molecular Diagnostics excluding HPV.
- Monitor cash generation, debt maturities, covenants, and the $300 million shareholder-return commitment, including the completed January 2017 transaction and remaining repurchases.
- Follow the GeneReader patent litigation, U.S. commercialization, product placements, and related consumables adoption.
- Review the sustainability and cash implications of the tax benefit, including uncertain tax positions and deferred tax assets.
- Assess acquisition integration and impairment risk, given the significant goodwill and intangible-asset balances.